Targeting the PINK1/Parkin-mediated mitophagy and SIRT1-PGC-1α-TFAM signaling pathways may provide a new potential therapeutic approach for P-MSCs in DKD. The gene discussed is TFAM; the disease is diabetic kidney disease.